[F-qi-FDG PET of the thyroid gland in Graves' disease].
OBJECTIVE
This study evaluates F-18-FDG PET of the thyroid in Graves' disease.


METHODS
Thirty patients were investigated the day before radioiodine therapy, 15 patients 3-10 days after radioiodine therapy. Twenty patients with cancer of the head or neck and normal thyroid function served as controls.


RESULTS
F-18-FDG uptake was higher in Graves' disease patients than in controls. Negative correlations of F-18-FDG uptake with half-life of radioiodine and absorbed radiation dose due to radioiodine therapy were found along with a positive correlation to autoantibody levels.


CONCLUSIONS
Thus F-18-FDG PET is likely to give information on the biological activity of Graves' disease as well as on early radiation effects.
Börner
A R
AR
Klinik und Poliklinik für Nuklearmedizin, Universität zu Köln. a.r.boerner@fz-juelich.de
Voth
E
E
Wienhard
K
K
Wagner
R
R
Schicha
H
H
D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000097:blood; D001692:Biological Transport; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D006111:Graves Disease / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000532:radiotherapy*; D006207:Half-Life; D006801:Humans; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D012016:Reference Values; D012044:Regression Analysis; D013961:Thyroid Gland / Q000000981:diagnostic imaging* / Q000378:metabolism; D014018:Tissue Distribution; D014055:Tomography, Emission-Computed
D001323:Autoantibodies; D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
F-18-FDG-PET der Schilddrüse bei Morbus Basedow.